German Breast group

Recent papers from German Breast group

1. Treatment-related neutropenia as predictor of response to adjuvant palbociclib in the PALLAS trial (ABCSG-42/AFT-05/BIG-14-13/PrE0109)JNCI Journal of the National Cancer Institute · 2026
2. Efficacy and Safety of EG12014 (Biosimilar Trastuzumab) Compared to Reference Trastuzumab in HER2-Positive Early Breast Cancer: A Phase III Randomized StudyAdvances in Therapy · 2026
3. Atezolizumab in early triple-negative breast cancer: the randomized phase 3 NSABP B-59/GeparDouze trialNature Medicine · 2026
4. Evaluation of a Tumor-Informed Molecular Residual Disease Assay in Early Triple-Negative Breast Cancer Treated With Neoadjuvant Chemotherapy, With or Without AtezolizumabJCO Precision Oncology · 2026
5. Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2- -associated high-risk HER2-negative early breast cancer: Updated results from the OlympiA phase III trialAnnals of Oncology · 2026
6. Surgical axillary intervention after neoadjuvant systemic therapy (NST) for early-stage breast cancer – Clinical significance of micrometastases: Data from five neoadjuvant studiesThe Breast · 2026
7. First-line ET plus palbociclib versus standard mono-chemotherapy in high-risk HR-positive/HER2-negative metastatic breast cancer and indication for chemotherapy: primary results from the randomized phase IV PADMA studyESMO Open · 2026
8. Final outcomes of the SOFT and TEXT phase III trials in premenopausal hormone receptor-positive early breast cancerAnnals of Oncology · 2026
9. Safety analyses of the INAVO120 randomised phase III trial of inavolisib or placebo with palbociclib–fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative, endocrine-resistant advanced breast cancerESMO Open · 2026
10. Secondary safety analysis of trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in DESTINY-Breast05: Clinical and demographic risk factors of interstitial lung disease (ILD) and radiation pneumonitis (RP).Journal of Clinical Oncology · 2026
11. Outcomes by lobular (lob) histology status at initial diagnosis in patients (pts) in the INAVO120 phase 3 trial with PIK3CA -mutated (mut), hormone receptor-positive (HR+), HER2-negative (HER2–), endocrine-resistant advanced breast cancer (aBC) treated with inavolisib (INAVO)/placebo (PBO) + palbociclib (PALBO) + fulvestrant (FULV).Journal of Clinical Oncology · 2026
12. 692P Discrepancies between clinician toxicity grading and patient-reported symptoms in high-risk early breast cancer: Evidence from the phase III PANTHER studyESMO Open · 2026
13. 78P Desmocollin 2 as a predictive marker for the development of distant metastasis (mets) in Breast Cancer (BC)ESMO Open · 2026
14. Exploratory analysis of PTEN deficiency by immunohistochemistry from the Phase III CAPItello-291 trialClinical Cancer Research · 2026
15. AGO Breast Committee recommendations for the surgical therapy of breast cancer: Working Group on Gynecologic Cancers (AGO) update 2026European Journal of Surgical Oncology · 2026
16. Challenges and strategies for delivering effective breast cancer care in conflict zones.2026
17. Concordance between clinician-reported toxicities and patient-reported symptom severity in early-stage breast cancer: an analysis of the randomized phase III PANTHER trialESMO Open · 2026
18. Optimization of Ki67 digital image analysis in breast cancer by automated tumor area identificationVirchows Archiv · 2026
19. Durvalumab in Combination With Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: Long-Term Analysis From the GeparNuevo TrialJournal of Clinical Oncology · 2026
20. Abstract CT013: Whole-exome sequencing tumor-informed circulating tumor DNA detection after completion of neoadjuvant treatment predicts non-pCR and distant recurrence in patients with early triple-negative breast cancer (TNBC) — Results from a sub-study of the NSABP B-59/GBG-96-GeparDouze TrialCancer Research · 2026